|Home | About | Journals | Submit | Contact Us | Français|
Institutional core facilities, both academic and pharmaceutical, are under a great deal of pressure today; efficient alternatives for Sanger DNA sequencing services are examined and the outcomes are illustrated via a case study. As with various other mature, well-characterized support functions, for example, oligo synthesis, outsourcing of Sanger DNA sequencing is increasing. Reasons include: 1. Preference to focus resources on mission-critical or complex, cutting edge technologies, 2. Pressures for cost-savings due to the economic downturn, fewer grants and severely decreased endowments, 3. Operational issues including the need to upgrade and maintain sequencers and/orstaffinglogistics that impact reliable turnaround, 4. Availability of external partnerships with economies of scale for Sanger DNA sequencing that have proven successful over the past 5 years. Many directors are interested in becoming aware and informed about Sanger DNA sequencing alternatives, and what the partnership alternative contributes to their institution. The decision to outsource should not be taken lightly; there is a continuum of choices and it is helpful to understand those that others have made. The informational poster will present a case study of such a DNA sequencing partnership and how it came about. The case study includes: 1. Background, 2. Technical considerations, 3. Types of partnerships & Institution's choice, 4. Implementations, 5. Enhancements, 6. Ongoing partnership managementResults discussed include structure of partnership, financial savings, space savings, turnaround savings, support gained, and other FAQs.